CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 294 enrolled
Drug / intervention
Pioglitazone/glimepiridedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02098746
NCT02098746N/ACompleted
CompareCT.gov

Sonias Combination Tablets LD Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone

Takeda·observational·Posted Mar 28, 2014·Updated Oct 18, 2016

In Brief

An observational study evaluating Pioglitazone/glimepiride for Type 2 Diabetes. Completed, enrolled 294 participants.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of long-term use of pioglitazone/glimepiride combination tablets (Sonias Combination Tablets LD) in patients with type 2 diabetes mellitus who respond poorly to pioglitazone hydrochloride monotherapy (pioglitazone at 15 mg/day) in the routine clinical setting.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 28, 2014
Enrollment StartJun 1, 2011
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 12.3 years ago

Interventions

Pioglitazone/glimepiridedrug

Pioglitazone/glimepiride combination tablets